Anika Therapeutics (ANIK) EV to FCF (2010 - 2026)

Anika Therapeutics (ANIK) has reported EV to FCF for 17 consecutive years, with 73.78 the latest figure, recorded in Q2 2026.

• On a quarterly basis, EV to FCF fell 62.01% year-over-year to 73.78 in Q2 2026; TTM through Jun 2026 was 280.04, a 298.65% increase from a year earlier, with the FY2025 full-year figure at 11.99, up 117.68% from the prior year.
• EV to FCF was 73.78 for Q2 2026 at Anika Therapeutics, down from 20.21 in the prior quarter.
• Over five years, EV to FCF peaked at 574.78 in Q4 2024 and troughed at 152.32 in Q4 2022.
• A 5-year average of 28.75 and a median of 24.41 in 2023 frame the typical range for EV to FCF.
• Across the five-year window, EV to FCF tumbled 229.58% in 2022 and jumped 335.88% in 2024, its largest moves.
• Over 5 years, EV to FCF stood at 152.32 in 2022, then jumped by 186.57% to 131.87 in 2023, then jumped by 335.88% to 574.78 in 2024, then slumped by 97.72% to 13.11 in 2025, then sank by 662.74% to 73.78 in 2026.
• The last three EV to FCF figures came in at 73.78 (Q2 2026), 20.21 (Q1 2026), and 13.11 (Q4 2025), per Business Quant data.